UK Markets closed

Global PEGylated Proteins Industry

ReportLinker
·25-min read

Global PEGylated Proteins Market to Reach US$1. 7 Billion by the Year 2027. Amid the COVID-19 crisis, the global market for PEGylated Proteins estimated at US$903. 9 Million in the year 2020, is projected to reach a revised size of US$1.

New York, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global PEGylated Proteins Industry" - https://www.reportlinker.com/p05957653/?utm_source=GNW
7 Billion by 2027, growing at a CAGR of 9.1% over the period 2020-2027.Consumables, one of the segments analyzed in the report, is projected to grow at a 8.5% CAGR to reach US$1.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Services segment is readjusted to a revised 10.4% CAGR for the next 7-year period. This segment currently accounts for a 29.9% share of the global PEGylated Proteins market.

The U.S. Accounts for Over 29.6% of Global Market Size in 2020, While China is Forecast to Grow at a 8.5% CAGR for the Period of 2020-2027

The PEGylated Proteins market in the U.S. is estimated at US$267.7 Million in the year 2020. The country currently accounts for a 29.61% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$288.9 Million in the year 2027 trailing a CAGR of 8.5% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR while Rest of European market (as defined in the study) will reach US$288.9 Million by the year 2027.We bring years of research experience to this 6th edition of our report. The 235-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.

Competitors identified in this market include, among others,

  • Biomatrik

  • Celares GmbH

  • Creative PEGWorks

  • Iris Biotech GmbH

  • Jenkem Technology Co., Ltd.

  • Laysan Bio, Inc.

  • MilliporeSigma

  • Nof American Corporation

  • Quanta Biodesign, Ltd.

  • Thermo Fisher Scientific, Inc.




Read the full report: https://www.reportlinker.com/p05957653/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Impact of Covid-19 and a Looming Global Recession
Global Competitor Market Shares
PEGylated Proteins Competitor Market Share Scenario Worldwide
(in %): 2018E

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for PEGylated Proteins
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 2: World Historic Review for PEGylated Proteins by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017

Table 3: World 15-Year Perspective for PEGylated Proteins by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2018 & 2027

Table 4: World Current & Future Analysis for Consumables by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 5: World Historic Review for Consumables by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017

Table 6: World 15-Year Perspective for Consumables by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027

Table 7: World Current & Future Analysis for Services by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 8: World Historic Review for Services by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017

Table 9: World 15-Year Perspective for Services by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2018 & 2027

Table 10: World Current & Future Analysis for Colony
Stimulating Factors by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2027

Table 11: World Historic Review for Colony Stimulating Factors
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017

Table 12: World 15-Year Perspective for Colony Stimulating
Factors by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2018 & 2027

Table 13: World Current & Future Analysis for Interferons by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 14: World Historic Review for Interferons by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017

Table 15: World 15-Year Perspective for Interferons by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027

Table 16: World Current & Future Analysis for Erythropoietin by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 17: World Historic Review for Erythropoietin by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017

Table 18: World 15-Year Perspective for Erythropoietin by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027

Table 19: World Current & Future Analysis for mAbs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 20: World Historic Review for mAbs by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017

Table 21: World 15-Year Perspective for mAbs by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2018 & 2027

Table 22: World Current & Future Analysis for Recombinant
Factor VIII by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2027

Table 23: World Historic Review for Recombinant Factor VIII by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017

Table 24: World 15-Year Perspective for Recombinant Factor VIII
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027

Table 25: World Current & Future Analysis for Other Protein
Types by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2018 through 2027

Table 26: World Historic Review for Other Protein Types by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2017

Table 27: World 15-Year Perspective for Other Protein Types by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2018 & 2027

Table 28: World Current & Future Analysis for Pharmaceutical &
Biotechnology Companies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2018 through 2027

Table 29: World Historic Review for Pharmaceutical &
Biotechnology Companies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 30: World 15-Year Perspective for Pharmaceutical &
Biotechnology Companies by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2018 & 2027

Table 31: World Current & Future Analysis for Contract Research
Organizations by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2027

Table 32: World Historic Review for Contract Research
Organizations by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 33: World 15-Year Perspective for Contract Research
Organizations by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2018 & 2027

Table 34: World Current & Future Analysis for Academic Research
Institutes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2018 through
2027

Table 35: World Historic Review for Academic Research
Institutes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 36: World 15-Year Perspective for Academic Research
Institutes by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2018 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES
Market Facts & Figures
US PEGylated Proteins Market Share (in %) by Company: 2018 & 2027
Market Analytics
Table 37: USA Current & Future Analysis for PEGylated Proteins
by Product - Consumables and Services - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 38: USA Historic Review for PEGylated Proteins by Product -
Consumables and Services Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017

Table 39: USA 15-Year Perspective for PEGylated Proteins by
Product - Percentage Breakdown of Value Sales for Consumables
and Services for the Years 2012, 2018 & 2027

Table 40: USA Current & Future Analysis for PEGylated Proteins
by Protein Type - Colony Stimulating Factors, Interferons,
Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2018 through 2027

Table 41: USA Historic Review for PEGylated Proteins by Protein
Type - Colony Stimulating Factors, Interferons, Erythropoietin,
mAbs, Recombinant Factor VIII and Other Protein Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 42: USA 15-Year Perspective for PEGylated Proteins by
Protein Type - Percentage Breakdown of Value Sales for Colony
Stimulating Factors, Interferons, Erythropoietin, mAbs,
Recombinant Factor VIII and Other Protein Types for the Years
2012, 2018 & 2027

Table 43: USA Current & Future Analysis for PEGylated Proteins
by End-Use - Pharmaceutical & Biotechnology Companies, Contract
Research Organizations and Academic Research Institutes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027

Table 44: USA Historic Review for PEGylated Proteins by End-Use -
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations and Academic Research Institutes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 45: USA 15-Year Perspective for PEGylated Proteins by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations and Academic Research Institutes for the Years
2012, 2018 & 2027

CANADA
Table 46: Canada Current & Future Analysis for PEGylated
Proteins by Product - Consumables and Services - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 47: Canada Historic Review for PEGylated Proteins by
Product - Consumables and Services Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 48: Canada 15-Year Perspective for PEGylated Proteins by
Product - Percentage Breakdown of Value Sales for Consumables
and Services for the Years 2012, 2018 & 2027

Table 49: Canada Current & Future Analysis for PEGylated
Proteins by Protein Type - Colony Stimulating Factors,
Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and
Other Protein Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2018 through 2027

Table 50: Canada Historic Review for PEGylated Proteins by
Protein Type - Colony Stimulating Factors, Interferons,
Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017

Table 51: Canada 15-Year Perspective for PEGylated Proteins by
Protein Type - Percentage Breakdown of Value Sales for Colony
Stimulating Factors, Interferons, Erythropoietin, mAbs,
Recombinant Factor VIII and Other Protein Types for the Years
2012, 2018 & 2027

Table 52: Canada Current & Future Analysis for PEGylated
Proteins by End-Use - Pharmaceutical & Biotechnology Companies,
Contract Research Organizations and Academic Research
Institutes - Independent Analysis of Annual Sales in US$
Million for the Years 2018 through 2027

Table 53: Canada Historic Review for PEGylated Proteins by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Research Organizations and Academic Research Institutes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 54: Canada 15-Year Perspective for PEGylated Proteins by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations and Academic Research Institutes for the Years
2012, 2018 & 2027

JAPAN
Table 55: Japan Current & Future Analysis for PEGylated
Proteins by Product - Consumables and Services - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 56: Japan Historic Review for PEGylated Proteins by
Product - Consumables and Services Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 57: Japan 15-Year Perspective for PEGylated Proteins by
Product - Percentage Breakdown of Value Sales for Consumables
and Services for the Years 2012, 2018 & 2027

Table 58: Japan Current & Future Analysis for PEGylated
Proteins by Protein Type - Colony Stimulating Factors,
Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and
Other Protein Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2018 through 2027

Table 59: Japan Historic Review for PEGylated Proteins by
Protein Type - Colony Stimulating Factors, Interferons,
Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017

Table 60: Japan 15-Year Perspective for PEGylated Proteins by
Protein Type - Percentage Breakdown of Value Sales for Colony
Stimulating Factors, Interferons, Erythropoietin, mAbs,
Recombinant Factor VIII and Other Protein Types for the Years
2012, 2018 & 2027

Table 61: Japan Current & Future Analysis for PEGylated
Proteins by End-Use - Pharmaceutical & Biotechnology Companies,
Contract Research Organizations and Academic Research
Institutes - Independent Analysis of Annual Sales in US$
Million for the Years 2018 through 2027

Table 62: Japan Historic Review for PEGylated Proteins by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Research Organizations and Academic Research Institutes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 63: Japan 15-Year Perspective for PEGylated Proteins by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations and Academic Research Institutes for the Years
2012, 2018 & 2027

CHINA
Table 64: China Current & Future Analysis for PEGylated
Proteins by Product - Consumables and Services - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 65: China Historic Review for PEGylated Proteins by
Product - Consumables and Services Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 66: China 15-Year Perspective for PEGylated Proteins by
Product - Percentage Breakdown of Value Sales for Consumables
and Services for the Years 2012, 2018 & 2027

Table 67: China Current & Future Analysis for PEGylated
Proteins by Protein Type - Colony Stimulating Factors,
Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and
Other Protein Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2018 through 2027

Table 68: China Historic Review for PEGylated Proteins by
Protein Type - Colony Stimulating Factors, Interferons,
Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017

Table 69: China 15-Year Perspective for PEGylated Proteins by
Protein Type - Percentage Breakdown of Value Sales for Colony
Stimulating Factors, Interferons, Erythropoietin, mAbs,
Recombinant Factor VIII and Other Protein Types for the Years
2012, 2018 & 2027

Table 70: China Current & Future Analysis for PEGylated
Proteins by End-Use - Pharmaceutical & Biotechnology Companies,
Contract Research Organizations and Academic Research
Institutes - Independent Analysis of Annual Sales in US$
Million for the Years 2018 through 2027

Table 71: China Historic Review for PEGylated Proteins by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Research Organizations and Academic Research Institutes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 72: China 15-Year Perspective for PEGylated Proteins by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations and Academic Research Institutes for the Years
2012, 2018 & 2027

EUROPE
Market Facts & Figures
European PEGylated Proteins Market: Competitor Market Share
Scenario (in %) for 2018 & 2027
Market Analytics
Table 73: Europe Current & Future Analysis for PEGylated
Proteins by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2018 through 2027

Table 74: Europe Historic Review for PEGylated Proteins by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017

Table 75: Europe 15-Year Perspective for PEGylated Proteins by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2018 & 2027

Table 76: Europe Current & Future Analysis for PEGylated
Proteins by Product - Consumables and Services - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 77: Europe Historic Review for PEGylated Proteins by
Product - Consumables and Services Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 78: Europe 15-Year Perspective for PEGylated Proteins by
Product - Percentage Breakdown of Value Sales for Consumables
and Services for the Years 2012, 2018 & 2027

Table 79: Europe Current & Future Analysis for PEGylated
Proteins by Protein Type - Colony Stimulating Factors,
Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and
Other Protein Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2018 through 2027

Table 80: Europe Historic Review for PEGylated Proteins by
Protein Type - Colony Stimulating Factors, Interferons,
Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017

Table 81: Europe 15-Year Perspective for PEGylated Proteins by
Protein Type - Percentage Breakdown of Value Sales for Colony
Stimulating Factors, Interferons, Erythropoietin, mAbs,
Recombinant Factor VIII and Other Protein Types for the Years
2012, 2018 & 2027

Table 82: Europe Current & Future Analysis for PEGylated
Proteins by End-Use - Pharmaceutical & Biotechnology Companies,
Contract Research Organizations and Academic Research
Institutes - Independent Analysis of Annual Sales in US$
Million for the Years 2018 through 2027

Table 83: Europe Historic Review for PEGylated Proteins by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Research Organizations and Academic Research Institutes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 84: Europe 15-Year Perspective for PEGylated Proteins by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations and Academic Research Institutes for the Years
2012, 2018 & 2027

FRANCE
Table 85: France Current & Future Analysis for PEGylated
Proteins by Product - Consumables and Services - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 86: France Historic Review for PEGylated Proteins by
Product - Consumables and Services Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 87: France 15-Year Perspective for PEGylated Proteins by
Product - Percentage Breakdown of Value Sales for Consumables
and Services for the Years 2012, 2018 & 2027

Table 88: France Current & Future Analysis for PEGylated
Proteins by Protein Type - Colony Stimulating Factors,
Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and
Other Protein Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2018 through 2027

Table 89: France Historic Review for PEGylated Proteins by
Protein Type - Colony Stimulating Factors, Interferons,
Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017

Table 90: France 15-Year Perspective for PEGylated Proteins by
Protein Type - Percentage Breakdown of Value Sales for Colony
Stimulating Factors, Interferons, Erythropoietin, mAbs,
Recombinant Factor VIII and Other Protein Types for the Years
2012, 2018 & 2027

Table 91: France Current & Future Analysis for PEGylated
Proteins by End-Use - Pharmaceutical & Biotechnology Companies,
Contract Research Organizations and Academic Research
Institutes - Independent Analysis of Annual Sales in US$
Million for the Years 2018 through 2027

Table 92: France Historic Review for PEGylated Proteins by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Research Organizations and Academic Research Institutes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 93: France 15-Year Perspective for PEGylated Proteins by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations and Academic Research Institutes for the Years
2012, 2018 & 2027

GERMANY
Table 94: Germany Current & Future Analysis for PEGylated
Proteins by Product - Consumables and Services - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 95: Germany Historic Review for PEGylated Proteins by
Product - Consumables and Services Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 96: Germany 15-Year Perspective for PEGylated Proteins by
Product - Percentage Breakdown of Value Sales for Consumables
and Services for the Years 2012, 2018 & 2027

Table 97: Germany Current & Future Analysis for PEGylated
Proteins by Protein Type - Colony Stimulating Factors,
Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and
Other Protein Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2018 through 2027

Table 98: Germany Historic Review for PEGylated Proteins by
Protein Type - Colony Stimulating Factors, Interferons,
Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017

Table 99: Germany 15-Year Perspective for PEGylated Proteins by
Protein Type - Percentage Breakdown of Value Sales for Colony
Stimulating Factors, Interferons, Erythropoietin, mAbs,
Recombinant Factor VIII and Other Protein Types for the Years
2012, 2018 & 2027

Table 100: Germany Current & Future Analysis for PEGylated
Proteins by End-Use - Pharmaceutical & Biotechnology Companies,
Contract Research Organizations and Academic Research
Institutes - Independent Analysis of Annual Sales in US$
Million for the Years 2018 through 2027

Table 101: Germany Historic Review for PEGylated Proteins by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Research Organizations and Academic Research Institutes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 102: Germany 15-Year Perspective for PEGylated Proteins
by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations and Academic Research Institutes for the Years
2012, 2018 & 2027

ITALY
Table 103: Italy Current & Future Analysis for PEGylated
Proteins by Product - Consumables and Services - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Table 104: Italy Historic Review for PEGylated Proteins by
Product - Consumables and Services Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2017

Table 105: Italy 15-Year Perspective for PEGylated Proteins by
Product - Percentage Breakdown of Value Sales for Consumables
and Services for the Years 2012, 2018 & 2027

Table 106: Italy Current & Future Analysis for PEGylated
Proteins by Protein Type - Colony Stimulating Factors,
Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and
Other Protein Types - Independent Analysis of Annual Sales in
US$ Million for the Years 2018 through 2027

Table 107: Italy Historic Review for PEGylated Proteins by
Protein Type - Colony Stimulating Factors, Interferons,
Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein
Types Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2017

Table 108: Italy 15-Year Perspective for PEGylated Proteins by
Protein Type - Percentage Breakdown of Value Sales for Colony
Stimulating Factors, Interferons, Erythropoietin, mAbs,
Recombinant Factor VIII and Other Protein Types for the Years
2012, 2018 & 2027

Table 109: Italy Current & Future Analysis for PEGylated
Proteins by End-Use - Pharmaceutical & Biotechnology Companies,
Contract Research Organizations and Academic Research
Institutes - Independent Analysis of Annual Sales in US$
Million for the Years 2018 through 2027

Table 110: Italy Historic Review for PEGylated Proteins by
End-Use - Pharmaceutical & Biotechnology Companies, Contract
Research Organizations and Academic Research Institutes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 111: Italy 15-Year Perspective for PEGylated Proteins by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations and Academic Research Institutes for the Years
2012, 2018 & 2027

UNITED KINGDOM
Table 112: UK Current & Future Analysis for PEGylated Proteins
by Product - Consumables and Services - Independent Analysis of
Annual Sales in US$ Million for the Years 2018 through 2027

Table 113: UK Historic Review for PEGylated Proteins by Product -
Consumables and Services Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2012 through 2017

Table 114: UK 15-Year Perspective for PEGylated Proteins by
Product - Percentage Breakdown of Value Sales for Consumables
and Services for the Years 2012, 2018 & 2027

Table 115: UK Current & Future Analysis for PEGylated Proteins
by Protein Type - Colony Stimulating Factors, Interferons,
Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein
Types - Independent Analysis of Annual Sales in US$ Million for
the Years 2018 through 2027

Table 116: UK Historic Review for PEGylated Proteins by Protein
Type - Colony Stimulating Factors, Interferons, Erythropoietin,
mAbs, Recombinant Factor VIII and Other Protein Types Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 117: UK 15-Year Perspective for PEGylated Proteins by
Protein Type - Percentage Breakdown of Value Sales for Colony
Stimulating Factors, Interferons, Erythropoietin, mAbs,
Recombinant Factor VIII and Other Protein Types for the Years
2012, 2018 & 2027

Table 118: UK Current & Future Analysis for PEGylated Proteins
by End-Use - Pharmaceutical & Biotechnology Companies, Contract
Research Organizations and Academic Research Institutes -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027

Table 119: UK Historic Review for PEGylated Proteins by End-Use -
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations and Academic Research Institutes Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 120: UK 15-Year Perspective for PEGylated Proteins by
End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations and Academic Research Institutes for the Years
2012, 2018 & 2027

REST OF EUROPE
Table 121: Rest of Europe Current & Future Analysis for
PEGylated Proteins by Product - Consumables and Services -
Independent Analysis of Annual Sales in US$ Million for the
Years 2018 through 2027

Table 122: Rest of Europe Historic Review for PEGylated
Proteins by Product - Consumables and Services Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2017

Table 123: Rest of Europe 15-Year Perspective for PEGylated
Proteins by Product - Percentage Breakdown of Value Sales for
Consumables and Services for the Years 2012, 2018 & 2027

Table 124: Rest of Europe Current & Future Analysis for
PEGylated Proteins by Protein Type - Colony Stimulating
Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor
VIII and Other Protein Types - Independent Analysis of Annual
Sales in US$ Million for the Years 2018 through 2027

Table 125: Rest of Europe Historic Review for PEGylated
Proteins by Protein Type - Colony Stimulating Factors,
Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and
Other Protein Types Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2017

Table 126: Rest of Europe 15-Year Perspective for PEGylated
Proteins by Protein Type - Percentage Breakdown of Value Sales
for Colony Stimulating Factors, Interferons, Erythropoietin,
mAbs, Recombinant Factor VIII and Other Protein Types for the
Years 2012, 2018 & 2027

Table 127: Rest of Europe Current & Future Analysis for
PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology
Companies, Contract Research Organizations and Academic
Research Institutes - Independent Analysis of Annual Sales in
US$ Million for the Years 2018 through 2027

Table 128: Rest of Europe Historic Review for PEGylated
Proteins by End-Use - Pharmaceutical & Biotechnology Companies,
Contract Research Organizations and Academic Research
Institutes Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2017

Table 129: Rest of Europe 15-Year Perspective for PEGylated
Proteins by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations and Academic Research Institutes for the Years
2012, 2018 & 2027

ASIA-PACIFIC
Table 130: Asia-Pacific Current & Future Analysis for PEGylated
Proteins by Product - Consumables and Services - Independent
Analysis of Annual Sales in US$ Million for the Years 2018
through 2027

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05957653/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001